Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FOOJX
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
LCB-71
|
|||||
| Synonyms |
LCB71; LCB 71; CS-5001; CS5001; CS 5001
Click to Show/Hide
|
|||||
| Organization |
LegoChem Biosciences, Inc.; ABL Bio, Inc.; CStone Pharmaceuticals Co. Ltd.; WuXi XDC Co., Ltd.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 6 Indication(s)
Acute lymphoblastic leukemia [ICD11:2B33]
Phase 1
Lymphoid leukaemia [ICD11:2B33]
Phase 1
Lymphoma [ICD11:2A85-2A90]
Phase 1
Mantle cell lymphoma [ICD11:2A85]
Phase 1
Non-small cell lung cancer [ICD11:2C25]
Phase 1
Triple negative breast cancer [ICD11:2C60-2C65]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
|
Antigen Info | ||||
| Payload Name |
Beta-glucuronide-linked pyrrolobenzodiazepine dimer (dPBD)
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Geranyl ketone pyrophosphate oxime ligation
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugation through the CaaX sequence at the C-terminal.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.